Location History:
- San Diego, CA (US) (2006)
- Cary, NC (US) (2006)
Company Filing History:
3 out of 91 
3 out of 1,271 
Years Active: 2006
Title: Gillian M Olins: Innovator in Platelet Aggregation Inhibition
Introduction
Gillian M Olins is a notable inventor based in Cary, NC (US). She has made significant contributions to the field of medicine, particularly in the area of platelet aggregation and thrombosis treatment. With a total of 3 patents, her work has the potential to impact various medical conditions associated with blood clotting.
Latest Patents
One of her latest patents is focused on a composition and method for inhibiting platelet aggregation. This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method also addresses the treatment of thrombosis. It involves administering a pharmaceutical composition that contains a therapeutically effective amount of P2Y receptor antagonist compounds. These compounds are effective in binding to the P2Y receptors on platelets, thereby inhibiting ADP-induced platelet aggregation. The P2Y receptor antagonist compounds useful for this invention include mononucleoside 5'-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates, along with their salts. Additionally, the invention provides novel compounds and pharmaceutical formulations comprising these mononucleoside and dinucleoside polyphosphates.
Career Highlights
Gillian has worked with several prominent organizations, including Inspire Pharmaceuticals, Inc. and the University of North Carolina at Chapel Hill. Her experience in these institutions has contributed to her expertise in the field of pharmaceutical sciences.
Collaborations
Some of her notable coworkers include Benjamin R Yerxa and James G Douglass, III. Their collaboration has likely enhanced the research and development of her innovative solutions.
Conclusion
Gillian M Olins is a pioneering inventor whose work in inhibiting platelet aggregation has the potential to transform treatment options for patients with thrombosis and related conditions. Her contributions to the field are invaluable and continue to inspire future innovations.